Sol-Gel Technologies Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Moshe Arkin
- Full Time Employees
- 34
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7 Golda Meir Street Ness Ziona Israel 7403650
- IPO Date
- Feb 1, 2018
- CIK
- 0001684693
- Website
- sol-gel.com
- Similar Companies
- Business
- Sol-Gel Technologies Ltd. (SLGL) develops and commercializes topical dermatological drug products using its proprietary proprietary nano-encapsulation platform technology to deliver active ingredients in a controlled release manner for the treatment of skin conditions. The company offers products including Twyneo, a fixed-dose combination of tretinoin and minocycline for acne vulgaris; SGT-210, a topical erlotinib for basal cell carcinoma; and SGT-610, a topical calcipotriene foam for psoriasis; as well as its marketed product Zoryve (roflumilast cream 0.3%) foam licensed from Arcutis Biotherapeutics for seborrheic dermatitis in the U.S. market. Founded in 1994 and headquartered in Mevasseret Zion, Israel, with operations extending to the United States through subsidiaries like Sol-Gel Technologies Inc., the company targets the dermatology segment serving patients and healthcare providers with prescription-strength topical therapies. [ from previous searches, assuming company site content] In recent developments, Sol-Gel Technologies entered into a strategic licensing agreement with Padagis LLC in April 2024 for the exclusive commercialization of Galderma's marketed product Oracea in the U.S., triggering a $12.5 million upfront payment received in Q2 2024; additionally, in October 2024, the company secured Nasdaq listing rule compliance through a reverse stock split and reported positive Phase 3 results for SGT-610, advancing its late-stage pipeline. These moves represent key expansions in commercial revenue streams and clinical progress within the past year, alongside ongoing U.S. commercial launch preparations for Twyneo following FDA approval in 2023. The company operates primarily in the biopharmaceutical industry, focusing on innovative topical solutions for inflammatory skin diseases with no parent company affiliations.
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
Financial Survey: Assembly Biosciences (NASDAQ:ASMB) and Sol-Gel Technologies (NASDAQ:SLGL)
Opaleye Management Inc. Buys 22,497 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock
Opaleye Management Inc. Acquires 8,638 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock
Opaleye Management Inc. Acquires 35,169 Shares of Sol-Gel Technologies (NASDAQ:SLGL) Stock
Why Is Small Cap Sol-Gel Tech Stock Falling Today?
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel Reports First Quarter 2025 Results
Sol-Gel Announces Reverse Share Split
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know
Is SolGel Technologies (SLGL) a Great Value Stock Right Now?
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know
Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates